The potential of adaptive licensing to boost investment
This article was originally published in SRA
Executive Summary
Small- and medium-sized drug firms should consider which of their development-stage assets might be candidates for adaptive licensing – a regulatory pathway that is being explored as a means of increasing the efficiency of the development cycle.